enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 1,699 shares, a decrease of 63.6% from the August 31st total of 4,663 shares. Based on an average daily trading volume, of 7,009 shares, the days-to-cover ratio is presently 0.2 days.

Key enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Reported short interest fell sharply to 1,699 shares as of September 15, down 63.6% from August 31, with only 0.2 days needed to cover. A reduction in bearish positioning can modestly improve sentiment and reduce potential short-selling pressure.
• Neutral Sentiment: A separate report dated September 24 listed short interest at zero shares, but this conflicts with the September 15 figure and may reflect different reporting dates or data issues. Investors should treat the short-interest information cautiously until it is reconciled.
• Negative Sentiment: ENGNW remains well below its 50-day and 200-day moving averages, indicating persistent technical weakness. The stock is also near the lower end of its 52-week range, and its relatively light trading volume may amplify price swings and make the shares less liquid.

enGene Price Performance

NASDAQ ENGNW traded down $0.12 during mid-day trading on Friday, reaching $0.22. 9,715 shares of the stock were exchanged, compared to its average volume of 15,893. enGene has a one year low of $0.11 and a one year high of $4.20. The stock has a 50 day simple moving average of $0.28 and a 200-day simple moving average of $0.85.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.